Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

NextCure Hopes Its Novel Target Therapies Will Treat Patients Not Helped By PD-1/L1 Inhibition

Nov 28 2018

• By Joseph Haas

Related Content

$1.6bn ARMO Buy Gives Lilly Its Most Advanced Immuno-Oncology Asset

May 11 2018

Immuno-Oncology Startup Snatches $67m In Series A

Jan 08 2016

Deal Watch: Amgen Outsources Celiac Drug To Provention; Lilly, NextCure Will Co-Discover IO Drugs

Nov 08 2018

Finance Watch: Biomatics Closes Second VC Fund; SVB Buys Leerink To Expand Life Science Services

Nov 16 2018

Related Companies

NextCure, Inc.

Eli Lilly and Company

Yale University

Pfizer Inc.

ARMO BioSciences, Inc.

Additional Topics

StartUps and SMEs ImmunoOncology Business Strategies Companies Research & Development Cancer BioPharmaceutical

More from Start-Ups & SMEs

More from Business

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window